Patients treated with Immune checkpoint inhibitors like anti CTL-4 anti PD-1 anti PD-L1 drugs, may develop side effects. As every tissue is sensitive to developing side effects and it's very important to recognize these side effects early on because the earlier they are in the control and the better for the patients.
In this OncologyPRO educational video of the "How to" series, John Haanen explains how to manage immunotherapy induced colitis, hepatitis and pneumonitis.
References:
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan, on behalf of the ESMO Guidelines Committee; Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up , Annals of Oncology, Volume 28, Issue suppl_4, 1 July 2017, Pages iv119–iv142, https://doi.org/10.1093/annonc/mdx225
View and download the ESMO Guidelines Slide Set on Management of toxicities from immunotherapy